ArticleCurrent cardiology reviews2026
Heart Failure in the Era of Precision Medicine: Advances, Challenges, and Future Directions.
Article in Current cardiology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence-enabled deep clinical phenotyping in heart failure with preserved ejection fraction: from patient subtypes to precision care.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart Failure (HF) remains a leading cause of morbidity and mortality worldwide, with a heterogeneous clinical spectrum requiring increasingly individualized care. Advances in pharmacotherapy, device interventions, and precision medicine have transformed HF management. This review synthesizes recent developments, persistent challenges, and emerging opportunities in HF care.
methodsWe performed a narrative review of landmark clinical trials, guideline updates, and high-impact studies published between January 2020 and December 2024. Sources included PubMed/MEDLINE, Scopus, Web of Science, and major cardiology society publications. Studies were selected based on clinical relevance, robustness of evidence, and applicability to contemporary practice.
resultsRecent evidence supports the use of Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) across the EF spectrum, expanding HF treatment beyond traditional ejection fraction categories. Novel therapies, including vericiguat, omecamtiv mecarbil, and transthyretin amyloidosis- specific drugs, have addressed previously unmet needs. Precision medicine approaches, incorporating genetic testing, biomarker-guided care, and advanced imaging, show promise in tailoring interventions. However, disparities in access, underrepresentation in clinical trials, and implementation barriers persist. DISCUSSION: The integration of novel pharmacologic agents, disease-specific therapies, and precision medicine tools has broadened the therapeutic landscape for HF. Ongoing challenges include ensuring equitable access, validating emerging technologies, and translating trial findings into practical applications in real-world settings. Multidisciplinary care models and pragmatic clinical trials will be essential to address these gaps.
conclusionAdvances in HF therapeutics and precision medicine are reshaping patient care. Strategic implementation, equitable access, and continued innovation are critical to improving outcomes across diverse HF populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.